Warner D L, Burke T G
College of Pharmacy, Division of Medical Chemistry and Pharmaceutics, University of Kentucky, Lexington 40506, USA.
J Chromatogr B Biomed Sci Appl. 1997 Mar 28;691(1):161-71. doi: 10.1016/s0378-4347(96)00426-4.
The well documented hydrolysis of the alpha-hydroxy-delta-lactone ring moiety in camptothecin and related analogues is routinely monitored using high-performance liquid chromatography (HPLC). Previous HPLC separations of the lactone and carboxylate forms of camptothecins have often required mobile phases containing three to four components; ion-pairing reagent to provide adequate retention of the carboxylate form of the drug; buffer to control the ionic strength and pH of the mobile phase; acetonitrile to control the retention of the lactone form and, in some instances, sodium dodecyl sulfate to reduce peak tailing. Because of the complexity of the mobile phases employed, development of these assays can be a laborious process, requiring re-optimization for each new analogue. In this study, we have developed a simple HPLC methodology for the simultaneous separation of the lactone and carboxylate forms of numerous camptothecin analogues. The mobile phase employed includes only triethylamine acetate (TEAA) buffer and acetonitrile. In this application, triethylamine serves multiple roles; as the ion-pairing reagent, as a masking agent for underivatized silanols and as the major buffer component. By altering only the composition of TEAA buffer with respect to acetonitrile, method development becomes a more streamlined and time efficient process. In this publication, we present the simultaneous separation of the lactone and carboxylate forms of camptothecin and four related analogues, namely, topotecan, GI147211, 10-aminocamptothecin and the CPT-11-SN-38 drug-metabolite pair. It is proposed that this new mobile phase, consisting of only triethylamine acetate buffer and acetonitrile, can be used for the analysis of the several camptothecin derivatives presently in clinical trials as well as the numerous other analogues in preclinical development.
喜树碱及相关类似物中α-羟基-δ-内酯环部分的水解已有充分记录,通常使用高效液相色谱法(HPLC)进行监测。以往对喜树碱内酯和羧酸盐形式的HPLC分离通常需要含有三到四种成分的流动相;离子对试剂以确保药物羧酸盐形式有足够的保留;缓冲液以控制流动相的离子强度和pH值;乙腈以控制内酯形式的保留,在某些情况下还需要十二烷基硫酸钠以减少峰拖尾。由于所采用流动相的复杂性,这些分析方法的开发可能是一个繁琐的过程,每种新类似物都需要重新优化。在本研究中,我们开发了一种简单的HPLC方法,用于同时分离多种喜树碱类似物的内酯和羧酸盐形式。所采用的流动相仅包括三乙胺乙酸盐(TEAA)缓冲液和乙腈。在本应用中,三乙胺发挥多种作用;作为离子对试剂、未衍生硅醇的掩蔽剂以及主要缓冲成分。通过仅改变TEAA缓冲液相对于乙腈的组成,方法开发变得更加简化且高效省时。在本出版物中,我们展示了喜树碱及其四种相关类似物(即拓扑替康、GI147211、10-氨基喜树碱以及CPT-11-SN-38药物代谢物对)的内酯和羧酸盐形式的同时分离。有人提出,这种仅由三乙胺乙酸盐缓冲液和乙腈组成的新流动相可用于分析目前正在进行临床试验的几种喜树碱衍生物以及临床前开发中的众多其他类似物。